JP2022106920A5 - - Google Patents

Download PDF

Info

Publication number
JP2022106920A5
JP2022106920A5 JP2022076713A JP2022076713A JP2022106920A5 JP 2022106920 A5 JP2022106920 A5 JP 2022106920A5 JP 2022076713 A JP2022076713 A JP 2022076713A JP 2022076713 A JP2022076713 A JP 2022076713A JP 2022106920 A5 JP2022106920 A5 JP 2022106920A5
Authority
JP
Japan
Prior art keywords
aryl
methyl
alkyl
alkoxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022076713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022106920A (ja
Filing date
Publication date
Priority claimed from JP2018556819A external-priority patent/JP7129703B2/ja
Application filed filed Critical
Publication of JP2022106920A publication Critical patent/JP2022106920A/ja
Publication of JP2022106920A5 publication Critical patent/JP2022106920A5/ja
Priority to JP2023215791A priority Critical patent/JP2024038012A/ja
Pending legal-status Critical Current

Links

JP2022076713A 2016-04-28 2022-05-06 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 Pending JP2022106920A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023215791A JP2024038012A (ja) 2016-04-28 2023-12-21 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662328857P 2016-04-28 2016-04-28
US62/328,857 2016-04-28
JP2018556819A JP7129703B2 (ja) 2016-04-28 2017-04-28 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
PCT/US2017/030080 WO2017189978A1 (en) 2016-04-28 2017-04-28 Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018556819A Division JP7129703B2 (ja) 2016-04-28 2017-04-28 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023215791A Division JP2024038012A (ja) 2016-04-28 2023-12-21 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Publications (2)

Publication Number Publication Date
JP2022106920A JP2022106920A (ja) 2022-07-20
JP2022106920A5 true JP2022106920A5 (https=) 2023-02-07

Family

ID=60160145

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018556819A Active JP7129703B2 (ja) 2016-04-28 2017-04-28 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP2022076713A Pending JP2022106920A (ja) 2016-04-28 2022-05-06 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP2023215791A Pending JP2024038012A (ja) 2016-04-28 2023-12-21 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018556819A Active JP7129703B2 (ja) 2016-04-28 2017-04-28 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023215791A Pending JP2024038012A (ja) 2016-04-28 2023-12-21 アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Country Status (7)

Country Link
US (2) US11192914B2 (https=)
EP (1) EP3448392A4 (https=)
JP (3) JP7129703B2 (https=)
CN (1) CN109689063B (https=)
CA (2) CA3295444A1 (https=)
EA (1) EA201892448A1 (https=)
WO (1) WO2017189978A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892448A1 (ru) * 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP2023521425A (ja) * 2020-04-14 2023-05-24 ヤンセン ファーマシューティカルズ,インコーポレーテッド E型肝炎の治療のためのアルキニルヌクレオシド類似体
CN115997016A (zh) 2020-04-27 2023-04-21 西克斯福德生物科学有限公司 包含具有模块化官能团的核酸纳米颗粒的组合物
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CN113621013B (zh) * 2021-09-17 2023-07-21 中国人民解放军军事科学院军事医学研究院 2`-乙炔基腺苷磷酰胺类衍生物及其制备方法和用途
CN117567310A (zh) * 2023-11-28 2024-02-20 重庆智合生物医药有限公司 一种神经酰胺np1的合成方法

Family Cites Families (447)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607925A (en) 1988-11-15 1997-03-04 Merrell Pharmaceuticals Inc. Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
UA6419A1 (uk) 1991-01-03 1994-12-29 Чеслав-Констянтин Альбінович Будревич Вітродвигун будревича
EP0627930A4 (en) 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6107027A (en) 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
GB9605293D0 (en) 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
AU5157998A (en) 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US6103706A (en) 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
US6010890A (en) 1997-04-29 2000-01-04 New York Blood Center, Inc. Method for viral inactivation and compositions for use in same
US6143752A (en) 1997-08-01 2000-11-07 Oren; Ran Method for preventing or arresting liver damage in humans
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
ES2186660T3 (es) 1997-09-21 2003-05-16 Schering Corp Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
EP1023901A4 (en) 1997-10-13 2004-10-27 Otsuka Pharma Co Ltd MEDICINES FOR HEPATITIS C AND THE USE THEREOF
FR2771637B1 (fr) 1997-12-01 2003-10-24 Hutchinson Utilisation d'un halogenure de dialkyldialkylammonium par voie parenterale dans les infections bacteriennes et virales
KR20010033028A (ko) 1997-12-11 2001-04-25 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 막-관련 바이러스 복제의 억제
CA2313049A1 (en) 1997-12-17 1999-06-24 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DE69943314D1 (de) 1998-02-12 2011-05-12 Kapil N Bhalla Sphingolipid-derivate und verfahren zu deren verwendung
US6475985B1 (en) 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
JP2000007578A (ja) 1998-06-24 2000-01-11 Hiroaki Okushin C型肝炎ウイルスの陰性化のための投薬システム
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
RU2158604C2 (ru) 1998-07-03 2000-11-10 Толоконская Наталья Петровна Способ лечения вирусного гепатита c
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
TR200101085T2 (tr) 1998-10-16 2001-08-21 Schering Corporation Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
AR022116A1 (es) 1998-12-18 2002-09-04 Schering Corp Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
WO2000037110A2 (en) 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
JP2000212099A (ja) 1999-01-19 2000-08-02 Mochida Pharmaceut Co Ltd ウイルス性肝炎治療剤
JP2002536424A (ja) 1999-02-13 2002-10-29 ピュアパルス テクノロジーズ インコーポレイテッド 広域スペクトルのパルス光を使用して病原体を不活性化する方法
US6589570B1 (en) 1999-04-12 2003-07-08 University Of Madras Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
HK1053126A1 (zh) 1999-07-22 2003-10-10 新生物生物公司 酶催化的治疗活化
WO2001012214A2 (en) 1999-08-13 2001-02-22 F. Hoffmann-La Roche Ag MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
US20050245502A1 (en) 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
KR100392292B1 (ko) 2000-01-07 2003-07-22 주식회사 펩트론 5원환 융합 방향족 헤테로사이클릭 화합물을 유효성분으로 하는 hcv 치료제 조성물
US6727267B2 (en) 2000-04-05 2004-04-27 Tularik Inc. NS5B HVC polymerase inhibitors
WO2001077371A1 (fr) 2000-04-07 2001-10-18 Shionogi & Co., Ltd. Procede de dosage de preincubation
ATE526423T1 (de) 2000-04-18 2011-10-15 Virco Bvba Verfahren zum messen des medikamentenwiderstands gegen hcv
US6415797B1 (en) 2000-07-07 2002-07-09 First Circle Medical, Inc. Treatment of human herpesviruses using hyperthermia
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
DK1385870T3 (da) 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
RO118842B1 (ro) 2000-08-02 2003-12-30 Cristian Paul Munteanu Metodă de tratament a limfoamelor maligne nonhodgkin de mică malignitate, asociate cu boală cronică de ficat de etiologie virală c
CA2417550A1 (en) 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
ES2272558T3 (es) 2000-10-12 2007-05-01 Viromics Gmbh Inhibidores del proteasoma para el tratamiento de infecciones causadas por virus de la hepatitis.
AP2003002796A0 (en) 2000-10-13 2003-06-30 Richard Boyd Disease prevention by reactivation of the thymus
AU2002213343A1 (en) 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
FR2815543B1 (fr) 2000-10-19 2003-10-24 Sedat Seringue d'auto-injection d'un melange extemporane
EP1333850B1 (en) 2000-10-20 2008-08-20 Genetics Institute, Inc. Use of il-13 inhibitors for the treatment of tumors
AU2002245081A1 (en) 2000-12-06 2002-07-16 The Trustees Of The University Of Pennsylvania Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
US6673775B2 (en) 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US6833351B2 (en) 2001-05-21 2004-12-21 Douglas T. Dieterich Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
MXPA03011793A (es) 2001-06-29 2004-04-02 Maxygen Holdings Ltd Formulaciones de interferon.
WO2003007981A1 (en) 2001-07-20 2003-01-30 Intermune, Inc. Methods of treating liver fibrosis
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
IL160882A0 (en) 2001-09-28 2004-08-31 Intermune Inc Method for treating hepatitis c virus infection in treatment failure patients
PL369129A1 (en) 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
CN1738635A (zh) 2001-10-05 2006-02-22 印特缪恩股份有限公司 用多阶段干扰素传递曲线治疗肝炎病毒感染的方法
WO2003037908A1 (en) 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
PE20030545A1 (es) 2001-10-31 2003-06-19 Schering Corp Formulaciones de jarabe de ribavirina
EP1444330A1 (en) 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
AUPR879601A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AU2002346686A1 (en) 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
US6906190B2 (en) 2002-01-04 2005-06-14 Ribapharm Inc. Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
RU2212248C1 (ru) 2002-01-21 2003-09-20 Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Способ лечения больных хроническим вирусным гепатитом c
JP2005522457A (ja) 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
CA2383243A1 (en) 2002-04-23 2003-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for inhibiting fibrogenesis
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003249659A1 (en) 2002-05-31 2003-12-19 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
ITMI20021860A1 (it) 2002-08-28 2004-02-29 Scalia Antonio Cassar Impiego dei triptani come agenti antivirali.
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
WO2004039996A1 (en) 2002-11-01 2004-05-13 Cadila Healthcare Limited Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
WO2004043435A2 (en) 2002-11-13 2004-05-27 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
AU2003295773A1 (en) 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
BRPI0407587A (pt) 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
US20070077225A1 (en) 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
EP1601368A2 (en) 2003-02-28 2005-12-07 Intermune, Inc. Methods and compositions for treatment of viral diseases
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
TWI269656B (en) 2003-03-05 2007-01-01 Original Image Co Ltd Therapeutical composition for hepatitis C
UA64191A (en) 2003-03-14 2004-02-16 Yevhenii Mykhailovych Neiko Method for treating chronic hepatitises of various etiology
US20040198840A1 (en) 2003-04-02 2004-10-07 Deloach Reuben Edwin Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
US20040258663A1 (en) 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US20050187170A1 (en) 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
JP2007537131A (ja) 2003-06-20 2007-12-20 ヴァイラル・ジェノミックス・インコーポレーテッド 抗ウイルス組成物および同一物を使用する方法
CA2532084A1 (en) 2003-07-11 2005-02-03 Oregon Health And Science University Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences
MD2549G2 (ro) 2003-07-18 2005-08-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Metodă de tratament a hepatitei virale cronice C.
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク C型肝炎ウイルス感染治療用のtlr7リガンド及びそのプロドラッグの投与
JPWO2005023289A1 (ja) 2003-09-08 2007-11-01 株式会社インテレクチャル・プロパティ・コンサルティング 慢性c型肝炎を治療するための医薬組成物
AR045870A1 (es) 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005038056A1 (en) 2003-10-14 2005-04-28 Intermune, Inc. Combination therapy for the treatment of viral diseases
US20050085528A1 (en) 2003-10-17 2005-04-21 Pfizer Inc. Parmaceutical
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
JP2007509950A (ja) 2003-10-27 2007-04-19 バーテックス ファーマシューティカルズ インコーポレイテッド Hcv処置の組合せ剤
UA68233A (en) 2003-11-25 2004-07-15 Univ Zaporizhia State Medical Method for treating chronic hepatitis c
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
EP2161273B1 (en) 2003-12-22 2015-04-15 K.U.Leuven Research & Development Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
US20070258946A1 (en) 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2005062949A2 (en) 2003-12-23 2005-07-14 Intermune, Inc. Method for treating hepatitis virus infection
DE10361944A1 (de) 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
US20080234182A1 (en) 2007-03-22 2008-09-25 Innovative Biologics, Inc. Blockers of pore-forming virulence factors and their use as anti-infectives
WO2006003521A1 (en) 2004-02-06 2006-01-12 Monash University High dose, short interval use of sulfated polysaccharides for the treatment of infections
AU2005219859A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
CA2563058C (en) 2004-04-22 2012-10-16 Howard J. Smith & Associates Pty Ltd Supportive treatment of liver disease
ES2361458T5 (es) 2004-05-04 2016-04-20 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para reducir las cantidades de genoma vírico de VHC en una célula diana
AR049635A1 (es) 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
EP1747233A4 (en) 2004-05-06 2007-04-25 COMPOUNDS FOR SPECIFIC VIRAL TARGET
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
CA2568008C (en) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
AR049297A1 (es) 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
US7671017B2 (en) 2004-07-14 2010-03-02 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1627641A1 (en) 2004-08-04 2006-02-22 Victor Eluwa Pharmaceutical compositions comprising metal oxides and uses thereof
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006037052A2 (en) 2004-09-27 2006-04-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Modulating mxa expression
DK1793844T3 (da) 2004-10-01 2011-03-21 Debiopharm Sa Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
RU2007116265A (ru) 2004-10-01 2008-11-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибирование протеазы ns3-ns4a вируса hcv
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
WO2006043153A2 (en) 2004-10-20 2006-04-27 Michel Xilinas Use of zinc and copper chelators for the treatment of viral diseases
US20060228333A1 (en) 2004-10-20 2006-10-12 Kye-Hyung Paik Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues
WO2006046039A2 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
TW201424733A (zh) 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
US7592315B2 (en) 2004-11-02 2009-09-22 Schering Corporation Peptide viral entry inhibitors
EP1827450A4 (en) 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
US20060105063A1 (en) 2004-11-18 2006-05-18 Kent Hann Synergic combination of compositions containing aloe vera isolates and their therapeutic application
WO2006063149A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
TW200633718A (en) 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
RU2007131267A (ru) 2005-01-17 2009-02-27 Йерини Аг (De) АНТАГОНИСТЫ РЕЦЕПТОРА С5a
US7655254B2 (en) 2005-02-03 2010-02-02 Intarcia Therapeutics, Inc. Implantable device for continuous delivery of interferon
KR20070102741A (ko) 2005-02-09 2007-10-19 미게닉스 인코포레이티드 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법
US20060198787A1 (en) 2005-02-18 2006-09-07 Larry Blatt Biomarkers for predicting liver fibrosis treatment efficacy
US8232240B2 (en) 2005-02-23 2012-07-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
EP2842559A3 (en) 2005-04-08 2015-03-18 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
US20060293267A1 (en) 2005-04-13 2006-12-28 University Of Massachusetts Dual functional oligonucleotides for use as anti-viral agents
US20060241144A1 (en) 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
WO2006119646A1 (en) 2005-05-13 2006-11-16 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP1881828A4 (en) 2005-05-20 2009-06-03 Valeant Res & Dev TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN
WO2006127482A1 (en) 2005-05-20 2006-11-30 Bioenvision, Inc. Methylene blue therapy of viral disease
MX2007014889A (es) 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
JP2008542380A (ja) 2005-05-31 2008-11-27 ノバルティス アクチエンゲゼルシャフト 鉄が病因に関与する肝臓疾患の処置
US7793040B2 (en) 2005-06-01 2010-09-07 Microsoft Corporation Content addressable memory architecture
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060276404A1 (en) 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
NZ563365A (en) 2005-06-02 2011-02-25 Schering Corp Combination of HCV protease inhibitors with a surfactant
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
AU2006252519B2 (en) 2005-06-02 2012-08-30 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20070207949A1 (en) 2005-06-02 2007-09-06 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US20070232527A1 (en) 2005-06-02 2007-10-04 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
EA016838B1 (ru) 2005-06-07 2012-07-30 Йельский Университет Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)
RU2293572C1 (ru) 2005-07-18 2007-02-20 Гюнтер Хаазе Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Hcv ns3蛋白酶抑制劑
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
KR20080033481A (ko) 2005-08-02 2008-04-16 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제의 억제제
WO2007021494A2 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
DE102005038768A1 (de) 2005-08-16 2007-02-22 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Borreliose
PL385229A1 (pl) 2005-08-19 2008-09-29 Vertex Pharmaceuticals Incorporated Sposoby i związki pośrednie
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
US7531164B2 (en) 2005-10-21 2009-05-12 Duke University Preventing bacterial or viral infectivity and composition containing infection preventing additive
IE20050723A1 (en) 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
WO2007056016A2 (en) 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
RU2306134C2 (ru) 2005-11-07 2007-09-20 Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" Способ базисного лечения хронического вирусного гепатита c
EP2392589A3 (en) 2005-11-11 2012-06-20 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
RU2326115C2 (ru) 2005-11-21 2008-06-10 Ефаг АО Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
WO2007064691A1 (en) 2005-12-02 2007-06-07 Nabil Habib Lab Treatment of cancer and other diseases
CA2632626C (en) 2005-12-09 2011-10-11 F. Hoffmann-La Roche Ag Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
RU2306934C1 (ru) 2005-12-28 2007-09-27 ГОУ ВПО Омская Государственная Медицинская Академия Способ лечения больных хроническим вирусным гепатитом c
CA2636527C (en) 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
MD20060037A (ro) 2006-01-24 2007-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Metodă de tratament al hepatitei virale acute C
WO2007092645A2 (en) 2006-02-09 2007-08-16 Schering Corporation Novel hcv inhibitor combinations and methods
MX2008010355A (es) 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP1993994A2 (en) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
WO2007109605A2 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CA2645566A1 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2007111866A2 (en) 2006-03-23 2007-10-04 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
WO2007130646A2 (en) 2006-05-04 2007-11-15 The Rockefeller University Hcv coreceptor and methods of use thereof
US20100256217A1 (en) 2006-05-22 2010-10-07 The Trustees Of The University Of Pennsylvania Antiviral inhibition of casein kinase ii
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
CA2654183A1 (en) 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
AU2007256393A1 (en) 2006-06-04 2007-12-13 Cellartis Ab Novel hepatocyte-like cells and hepatoblast-like cells derived from hBS cells
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
WO2007149382A2 (en) 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in treating hepatitis
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 억제제
US20080081791A1 (en) 2006-07-06 2008-04-03 Weida Huang Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
JP2009542698A (ja) 2006-07-07 2009-12-03 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルスホスフィナート化合物
NZ574605A (en) 2006-07-13 2011-11-25 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
WO2008022006A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
KR20090057035A (ko) 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
TW200815384A (en) 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
AU2007286754A1 (en) 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
US7655419B2 (en) 2006-08-25 2010-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
WO2008032227A2 (en) 2006-09-11 2008-03-20 Biomas, Ltd. Topical formulations of tellurium-containing compounds
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
WO2008033413A2 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2083825A4 (en) 2006-09-26 2009-11-04 Addiction Res Inst Inc HEPATITIS C TREATMENT COMPOSITIONS AND METHODS OF USING HEPATITIS C TREATMENT COMPOSITIONS
KR101057239B1 (ko) 2006-10-10 2011-08-16 에프. 호프만-라 로슈 아게 뉴클레오사이드 리보푸라노실 피리미딘의 제조
US7777395B2 (en) 2006-10-12 2010-08-17 Eastman Kodak Company Continuous drop emitter with reduced stimulation crosstalk
WO2008057209A1 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5290186B2 (ja) 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
WO2008143647A2 (en) 2006-11-29 2008-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating viral infection
CA2673111A1 (en) 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
RU2336096C1 (ru) 2006-12-14 2008-10-20 ООО Медицинский центр "Столица" Способ лечения гепатита с
RU2345787C2 (ru) 2006-12-25 2009-02-10 Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" Способ лечения хронического вирусного гепатита с
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2111227A1 (en) 2007-01-08 2009-10-28 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
WO2008089034A2 (en) 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
US7645732B2 (en) 2007-01-24 2010-01-12 Board Of Regents, The University Of Texas System Treating hepatitis C virus infection
BRPI0806945A2 (pt) 2007-02-01 2014-05-06 Tibotec Pharm Ltd Formas polimórficas de um inibidor macrocíclico de hcv
TW200838550A (en) * 2007-02-09 2008-10-01 Novartis Ag Organic compounds
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
CA2683383C (en) 2007-02-21 2016-01-05 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
DK2114924T3 (da) 2007-02-27 2012-04-10 Vertex Pharma Co-krystaller og farmaceutiske sammensætninger omfattende disse
WO2008106167A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
MD3477G2 (ro) 2007-03-21 2008-08-31 Николае БОДРУГ Metodă de tratament al hepatitei virale cronice C
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008124384A2 (en) 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
US20080269205A1 (en) 2007-04-27 2008-10-30 Ondine International, Ltd. Methods to prevent vertical transmission of infectious diseases
AU2008246195B2 (en) 2007-04-27 2014-06-05 Emergent Biodefence Operations Lansing Llc Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates
EP2160392A2 (en) 2007-05-03 2010-03-10 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EP2142215B1 (en) 2007-05-04 2012-03-07 Vertex Pharmceuticals Incorporated Combination therapy for the treatment of hcv infection
WO2008141227A1 (en) 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
JP2010528013A (ja) 2007-05-21 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Vx−950を含む用量形態およびそれらの投与レジメン
RU2348412C1 (ru) 2007-06-01 2009-03-10 Лариса Леонидовна Попова Способ профилактики рецидива хронического вирусного гепатита с после достижения вирусологической ремиссии
WO2008154248A1 (en) 2007-06-06 2008-12-18 Inova Health System Prognostic chronic hepatitis c biomarkers
EA019749B1 (ru) 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Противовирусные соединения
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
WO2009015336A2 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
CA2698038A1 (en) 2007-07-26 2009-01-29 Entra Pharmaceuticals Inc. Systems and methods for delivering drugs
US20100254942A1 (en) 2007-08-03 2010-10-07 Biotron Limited Hepatitis c antiviral compositions and methods
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
WO2009026292A1 (en) 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
WO2009033183A2 (en) 2007-09-08 2009-03-12 University Of Florida Research Foundation Compounds and methods for treatment of hcv and conditions associated with cd81 binding
US20090076100A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched gsk625433
EP2489369A1 (en) 2007-09-14 2012-08-22 Merck Sharp & Dohme Corp. A method of treating Hepatitis C patients
CN101918369B (zh) 2007-09-17 2016-02-24 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
PL2639226T3 (pl) 2007-09-17 2017-02-28 Abbvie Bahamas Ltd. Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
PA8796201A1 (es) 2007-09-17 2009-04-23 Abbott Lab Agentes anti-infecciosos y su uso
JP5715820B2 (ja) 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
US20090082366A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
US20090082414A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched viramidine
EP2205255B8 (en) 2007-10-03 2015-09-30 Sabell Corporation Herbal compositions and methods for treating hepatic disorders
WO2009046369A2 (en) 2007-10-05 2009-04-09 Medtronic, Inc. Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
WO2009061395A2 (en) 2007-11-05 2009-05-14 Vertex Pharmaceuticals Incorporated Hcv combination therapies
ES2374117T3 (es) 2007-11-15 2012-02-13 Madaus Gmbh Componente de silibinina para el tratamiento de la hepatitis.
CA2709032C (en) 2007-12-21 2016-02-23 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
CA2710144A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
EP2234623A4 (en) 2007-12-27 2012-03-28 Epiphany Biosciences ANTIVIRAL CONNECTIONS
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
JP5283106B2 (ja) 2008-03-14 2013-09-04 国立大学法人 熊本大学 C型肝炎ウイルス阻害剤
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110045001A1 (en) 2008-03-28 2011-02-24 Biontex Laboratories Gmbh Transfection results of non-viral gene delivery systems by influencing of the innate immune system
MX2010011307A (es) 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
MX2010011580A (es) 2008-04-23 2010-11-09 Vertex Pharma Tratamiento de infecciones por virus de hepatitis c con telaprevir (vx-950) en pacientes que no responden al tratamiento con interferon-alfa-2a-2b pegilado y ribavirina.
DE102008029669A1 (de) 2008-05-16 2009-11-19 Schlaak, Jörg Friedrich, Prof. Dr. med. Neue Therapeutika für die Hepatitis-Therapie
US20110218512A1 (en) 2008-06-03 2011-09-08 Aethlon Medical, Inc. Enhanced antiviral therapy methods and devices
AU2009255994B2 (en) 2008-06-05 2014-07-17 Bristol-Myers Squibb Company Use of pegylated Type III Interferons for the treatment of hepatitis C
JP2011522862A (ja) 2008-06-10 2011-08-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テラプレビル(Telaprevir)投薬養生法
WO2009152589A1 (en) 2008-06-17 2009-12-23 Universidade Federal De Minas Gerais-Ufmg Use of paf receptor for treating infections caused by flaviviridae
PT2540350E (pt) 2008-07-22 2014-08-27 Merck Sharp & Dohme Combinações de um composto de quinoxalina macrocílico o qual é um inibidor da protease ns3 do hcv com outros agentes do hcv
WO2010011343A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Methods for treating viral disorders
RU2373952C1 (ru) 2008-07-30 2009-11-27 Юрий Михайлович Амбалов Способ лечебного питания больных хроническим гепатитом с, получающих комплексную противовирусную терапию
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
JP2011530519A (ja) 2008-08-06 2011-12-22 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物を用いたc型肝炎の治療または予防の方法
KR101647520B1 (ko) 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
WO2010017432A1 (en) 2008-08-07 2010-02-11 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010020676A1 (en) 2008-08-20 2010-02-25 Vib Vzw The use of topoisomerase type i inhibitors to treat viral infections
JP2012501345A (ja) 2008-08-28 2012-01-19 バーテックス ファーマシューティカルズ インコーポレイテッド Hcv遺伝子型の分析
CN102137682B (zh) 2008-08-29 2014-07-02 国立大学法人大阪大学 抗丙型肝炎病毒组合物
MX2011002312A (es) 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
PE20130307A1 (es) 2008-09-16 2013-03-22 Boehringer Ingelheim Int Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv
CA2737376A1 (en) 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
WO2010031832A2 (en) 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
JP2012503669A (ja) 2008-09-24 2012-02-09 バーテックス ファーマシューティカルズ インコーポレイテッド 肝炎を治療するためのpeg−インターフェロン、リバビリンおよびvx−950を含む治療レジメ
EP2334379A2 (en) 2008-09-26 2011-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
US9006285B2 (en) 2008-09-30 2015-04-14 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for hepatitis C
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
EP2352829A1 (en) 2008-10-08 2011-08-10 Charlotte-Mecklenburg Hospital Authority doing business as Carolinas Medical Center Treating hepatitis c virus infection with over-expression of microrna-196
EP2358736A1 (en) 2008-10-15 2011-08-24 Intermune, Inc. Therapeutic antiviral peptides
WO2010049438A2 (en) 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
WO2010053942A1 (en) 2008-11-05 2010-05-14 Vertex Pharmaceuticals Incorporated Methods for treating hepatitis c virus infection
KR20110087297A (ko) 2008-11-21 2011-08-02 베링거 인겔하임 인터내셔날 게엠베하 경구 투여용의 강력한 hcv 억제제의 약제학적 조성물
EA022134B1 (ru) 2008-12-10 2015-11-30 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
WO2010066112A1 (en) 2008-12-11 2010-06-17 The University Of Hong Kong siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION
CN102257159A (zh) 2008-12-18 2011-11-23 弗·哈夫曼-拉罗切有限公司 用于hcv治疗应答的生物标志物
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
EP2808402A3 (en) 2008-12-29 2015-03-25 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment
US8840934B2 (en) 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
US8759318B2 (en) 2009-01-09 2014-06-24 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
RU2398582C1 (ru) 2009-01-19 2010-09-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью
WO2010093843A2 (en) 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
WO2010101649A2 (en) 2009-03-05 2010-09-10 Pablo Gastaminza Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
MX2011010047A (es) 2009-03-25 2011-10-11 Abbott Lab Compuestos antivirales y usos de los mismos.
SG174214A1 (en) 2009-03-25 2011-10-28 Abbott Lab Antiviral compounds and uses thereof
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
PL2421527T3 (pl) 2009-04-25 2018-10-31 F.Hoffmann-La Roche Ag Sposoby poprawy właściwości farmakokinetycznych
HUE030465T2 (hu) 2009-05-13 2017-05-29 Antivirális vegyületek
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
JP5469744B2 (ja) 2009-05-21 2014-04-16 メルク・シャープ・アンド・ドーム・コーポレーション インターフェロンアルファ応答に関連する遺伝子マーカー
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AR077138A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Composiciones farmaceuticas utiles para tratar el vhc
US20100324060A1 (en) 2009-06-23 2010-12-23 Gilead Sciences, Inc. Pharmaceutical compositions useful for treating hcv
AR077125A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Combinaciones farmaceuticas utiles para tratar el vhc
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
MY154683A (en) 2009-07-07 2015-07-15 Boehringer Ingelheim Int Pharmaceutical composition for a hepatitis c viral protease inhibitor
RU2400229C1 (ru) 2009-07-13 2010-09-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С, ГЕНОТИПОМ 3а
EP2467144A1 (en) 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
WO2011013019A1 (en) 2009-07-31 2011-02-03 Centre Hospitalier Universitaire Vaudois Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients
EP2470189A4 (en) 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
TW201116540A (en) 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
WO2011056630A2 (en) 2009-10-27 2011-05-12 Trustees Of Boston University Small molecule inhibitors of hepatitis c virus
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
AU2010325065A1 (en) 2009-11-09 2012-05-24 Merck Sharp & Dohme Corp. Markers associated with ribavirin-induced anemia
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011066260A2 (en) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
PH12012501216A1 (en) 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
CA3009891C (en) 2009-12-23 2020-09-15 Novartis Ag Lipids, lipid compositions, and methods of using them
RU2424794C1 (ru) 2009-12-30 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО УГМА Росздрава) Способ лечения врожденного гепатита с у детей первого года жизни
RU2012136824A (ru) 2010-01-29 2014-03-10 Вертекс Фармасьютикалз Инкорпорейтед Способы лечения вирусной инфекции гепатита с
NZ602288A (en) 2010-03-10 2014-02-28 Abbvie Bahamas Ltd Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011156337A2 (en) 2010-06-07 2011-12-15 Abbott Laboratories Macrocyclic hepatitis c serine protease inhibitors
WO2011156757A1 (en) 2010-06-10 2011-12-15 Gilead Sciences, Inc. Combination of anti-hcv compounds with ribavirin for the treatment of hcv
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CA2745102A1 (en) 2010-06-29 2011-12-29 Medicorp Institute Of Canada Pharmaceutical composition and method of use to improve organ function
RU2429877C1 (ru) 2010-06-30 2011-09-27 Общество с ограниченной ответственностью "ИНГИЛС" Способ лечения хронического вирусного гепатита с
US20120014912A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition
CA2805748A1 (en) 2010-07-16 2012-01-19 Shashank Shekhar Process for preparing n-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide
AU2011283008A1 (en) 2010-07-30 2013-01-24 Merck Sharp & Dohme Corp. Inhibition of CYP3A drug metabolism
US20120196272A1 (en) 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
CA2811752A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
CA2813093A1 (en) 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
TWI451439B (zh) 2010-12-10 2014-09-01 Phison Electronics Corp 記憶體儲存裝置、其記憶體控制器與資料寫入方法
JP5906253B2 (ja) 2010-12-16 2016-04-20 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
WO2012083164A1 (en) 2010-12-16 2012-06-21 Abbott Laboratories Anti-viral compounds
US20130273005A1 (en) 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
JP2014510155A (ja) 2011-04-06 2014-04-24 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス組み合わせ治療薬
WO2012175733A1 (en) 2011-06-23 2012-12-27 Santaris Pharma A/S Hcv combination therapy
WO2013000856A1 (en) 2011-06-30 2013-01-03 Santaris Pharma A/S Hcv combination therapy
JP2014520772A (ja) 2011-06-30 2014-08-25 ステラ・アンパルトセルスカブ Hcv併用療法
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013025975A1 (en) 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013028953A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Combination treatments for hepatitis c
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US20140328799A1 (en) 2011-10-31 2014-11-06 Steven S. Carroll Compositions useful for the treatment of viral diseases
US20130137084A1 (en) 2011-11-28 2013-05-30 Roche Molecular Systems, Inc. Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
ES2671478T3 (es) 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
US20140080886A1 (en) 2012-09-18 2014-03-20 Abbvie Inc. Methods for Treating HCV
PL2897611T3 (pl) 2012-09-18 2020-03-31 Abbvie Inc. Sposób leczenia wirusowego zapalenia wątroby typu C
JP2016501200A (ja) 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
US9598457B2 (en) * 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR20210013344A (ko) 2013-03-14 2021-02-03 애브비 인코포레이티드 C형 간염 치료용 2가지 항바이러스제의 병용물
JP6563894B2 (ja) 2013-03-14 2019-08-21 アッヴィ・インコーポレイテッド Hcv患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用
AU2014302711A1 (en) * 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015048744A2 (en) * 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015054465A1 (en) * 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3082808A1 (en) 2013-12-19 2016-10-26 AbbVie Inc. Methods for treating liver transplant recipients
MA40031A (fr) * 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
HUE051986T2 (hu) * 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
WO2016014527A2 (en) * 2014-07-21 2016-01-28 Achillion Pharmaceuticals, Inc. Stabilized nucleotides for medical treatment
MA41441A (fr) * 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US9980865B2 (en) * 2015-03-30 2018-05-29 Christopher Miranda Elevating wheelchair
EA201892448A1 (ru) * 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Similar Documents

Publication Publication Date Title
JP2022106920A5 (https=)
JP2019515930A5 (https=)
HRP20220911T1 (hr) Sastav nukleotida i nukleozida i njihova uporaba
JP2019525905A5 (https=)
IL298529A (en) Inhibitors of cysteine proteases and methods of use thereof
JP2014504643A5 (https=)
TW202317144A (zh) 口服生物可利用的核苷類似物
KR20210050594A (ko) N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
JP2014515377A5 (https=)
CA2498572A1 (en) Macrocyclic peptides active against the hepatitis c virus
JP2013537905A5 (https=)
JP2013532725A5 (https=)
IL207468A (en) HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections
JP2013514359A5 (https=)
JP2012504132A5 (https=)
CA2729168A1 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
JP2012504129A5 (https=)
JP2012528161A5 (https=)
JP2013538235A5 (https=)
JP2015535853A5 (https=)
EA022127B1 (ru) Ингибиторы вируса гепатита с
JP2012511004A5 (https=)
RU2012101881A (ru) Производные азапептидов
JP2014522809A5 (https=)
JP2017503005A5 (https=)